Holen Sie sich die Stockscreener-App
4.27
23.05%
0.80
Handel nachbörslich:
4.40
0.13
+3.04%
Rocket Pharmaceuticals Inc Aktie (RCKT) Neueste Nachrichten
Rocket Pharmaceuticals Shares Surge after FDA Accepts Drug Application Resubmission - MarketScreener
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment o - PharmiWeb.com
Rocket Pharmaceuticals (RCKT) Resubmitted Gene Therapy Applicati - GuruFocus
Rocket Pharma says gene therapy gets FDA review (RCKT:NASDAQ) - Seeking Alpha
FDA Accepts Rocket Pharmaceuticals' Resubmission for Kresladi Ge - GuruFocus
FDA Accepts Rocket Pharmaceuticals' BLA Resubmission for Rare Genetic Disorder Treatment - MarketScreener
Why Rocket Pharma Is Rising In Pre-market? - Nasdaq
Rocket Pharmaceuticals’ FDA Resubmission for KRESLADI™ Accepted - TipRanks
FDA accepts Rocket Pharmaceuticals’ gene therapy BLA for rare disease - Investing.com
FDA accepts Rocket Pharmaceuticals' resubmitted gene therapy application - StreetInsider
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Yahoo Finance
How Rocket Pharmaceuticals Inc. Equity Warrant stock reacts to inflationary pressuresMarket Performance Recap & Risk Controlled Stock Alerts - newser.com
Will Rocket Pharmaceuticals Inc. stock go up soonJuly 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
Chart based analysis of Rocket Pharmaceuticals Inc. trendsWeekly Investment Recap & Weekly Top Stock Performers List - newser.com
Will Rocket Pharmaceuticals Inc. Equity Warrant stock benefit from upcoming earnings reportsJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
Lobbying Update: $30,000 of ROCKET PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Heatmap analysis for Rocket Pharmaceuticals Inc. Equity Warrant and competitors2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com
Will a bounce in Rocket Pharmaceuticals Inc. offer an exitJuly 2025 Analyst Calls & High Accuracy Trade Alerts - newser.com
Why Rocket Pharmaceuticals Inc. stock is in analyst buy zoneMarket Trend Summary & Reliable Volume Spike Trade Alerts - newser.com
Can a trend reversal in Rocket Pharmaceuticals Inc. Equity Warrant lead to recoveryDip Buying & Stock Portfolio Risk Management - newser.com
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Is Rocket Pharmaceuticals Inc. Equity Warrant stock bottoming outQuarterly Risk Review & Free Real-Time Market Sentiment Alerts - newser.com
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Should you hold or exit Rocket Pharmaceuticals Inc. now2025 Trading Volume Trends & Real-Time Buy Signal Notifications - newser.com
Published on: 2025-10-10 06:17:17 - newser.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-10 04:39:16 - newser.com
Building trade automation scripts for Rocket Pharmaceuticals Inc. Equity Warrant2025 Macro Impact & Step-by-Step Trade Execution Guides - newser.com
How to use Fibonacci retracement on Rocket Pharmaceuticals Inc. Equity WarrantMarket Volume Report & High Win Rate Trade Alerts - newser.com
How sentiment analysis helps forecast Rocket Pharmaceuticals Inc. Equity WarrantPortfolio Update Report & Weekly High Potential Stock Alerts - newser.com
Will Rocket Pharmaceuticals Inc. (9IP1) stock profit from fiscal stimulusEarnings Beat & Intraday High Probability Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Reach Out - ACCESS Newswire
How to manage a losing position in Rocket Pharmaceuticals Inc. Equity Warrant2025 AllTime Highs & Free Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-09 05:44:17 - newser.com
Published on: 2025-10-09 03:18:17 - newser.com
Automated trading signals detected on Rocket Pharmaceuticals Inc. Equity WarrantWeekly Market Report & Safe Entry Point Identification - newser.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
What drives Rocket Pharmaceuticals Inc stock priceBollinger Bands Signals & Free Dynamic Capital Growth - earlytimes.in
Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102 - CGTLive®
How Rocket Pharmaceuticals Inc. Equity Warrant stock reacts to global recession fearsJuly 2025 Trends & Risk Controlled Daily Trade Plans - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock ready for a breakout2025 Trading Recap & Verified Swing Trading Watchlists - newser.com
Rocket Pharmaceuticals Inc. Equity Warrant stock volume spike explainedPortfolio Growth Summary & High Accuracy Swing Entry Alerts - newser.com
Using AI based signals to follow Rocket Pharmaceuticals Inc. Equity WarrantMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Reach Out - ACCESS Newswire
Combining price and volume data for Rocket Pharmaceuticals Inc. Equity WarrantEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Real time social sentiment graph for Rocket Pharmaceuticals Inc. Equity WarrantTrade Signal Summary & Daily Chart Pattern Signal Reports - newser.com
Is Rocket Pharmaceuticals Inc. Equity Warrant stock positioned well for digital economyGap Up & Community Verified Trade Signals - newser.com
Understanding Rocket Pharmaceuticals Inc. Equity Warrant’s price movementJuly 2025 PreEarnings & Accurate Intraday Trade Tips - newser.com
Is now a turning point for Rocket Pharmaceuticals Inc.2025 Historical Comparison & AI Powered Buy and Sell Recommendations - newser.com
Published on: 2025-10-05 06:51:42 - newser.com
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):